BGNE

BeiGene, Ltd. [BGNE] Stock Forecast

Q: What is BeiGene, Ltd. stock symbol ?

BeiGene, Ltd. is a US stock, located in Cambridge of Ma and trading under the symbol BGNE

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BGNE Stock Summary

Earnings have grown 73.65% per last year.

BGNE has more than 4 years of cash runway (55 months)

Earnings are expected to fall -100% next year

Top 10 Correlated ETFs

BGNE

Top 10 Correlated Stocks

BGNE

In the News

BGNE Financial details

Company Rating

Neutral

Market Cap

15.53B

Income

-881.71M

Revenue

2.46B

Book val./share

33.99

Cash/share

30.61

Dividend

Dividend %

Employees

10.6K

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

-17.71

Forward P/E

PEG

3.13

P/S

6.81

P/B

4.41

P/C

4.32

P/FCF

-9.54

Quick Ratio

1.98

Current Ratio

2.32

Debt / Equity

0.26

LT Debt / Equity

0.06

EPS (TTM)

-8.45

EPS next Y

EPS next Q

EPS this Y

-56.51%

EPS next Y

EPS next 5Y

EPS last 5Y

-11.8%

Revenue last 5Y

41.84%

Revenue Q/Q

-18.8%

EPS Q/Q

-271.36%

SMA20

-15.48%

SMA50

-6.58%

SMA100

-25.26%

Inst Own

41.97%

Inst Trans

0.93%

ROA

-15%

ROE

-23%

ROC

-0.3%

Gross Margin

66%

Oper. Margin

-49%

Profit Margin

-36%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

132.95-270.57

52W High

-51.06%

52W Low

+0.1%

RSI

Rel Volume

0.6

Avg Volume

261.91K

Volume

156.98K

Perf Week

-14.21%

Perf Month

-17.17%

Perf Quarter

-20.63%

Perf Half Y

-24.04%

Beta

0.627

Volatility

6.18%, 11.33%

Prev Close

-1.43%

Price

132.13

Change

-5.74%

BGNE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	7.13	3.7	12.68	13.73	23.55
Net income per share	-15.83	-19.17	-15.23	-19.43	-8.45
Operating cash flow per share	-12.49	-15.38	-14	-14.51	-11.09
Free cash flow per share	-15.13	-18.12	-17.39	-19.06	-16.66
Cash per share	16.36	55.72	71.32	43.97	30.52
Book value per share	16.29	46.35	67.28	42.5	33.89
Tangible book value per share	15.41	45.71	66.17	41.58	33.17
Share holders equity per share	16.29	46.35	67.28	42.5	33.89
Interest debt per share	4.77	6.74	7.32	9.15	9.06
Market cap	9.95B	21.57B	25.14B	22.68B	18.83B
Enterprise value	9.61B	20.75B	21.46B	19.7B	16.57B
P/E ratio	-10.47	-13.48	-17.79	-11.32	-21.35
Price to sales ratio	23.25	69.83	21.37	16.02	7.66
POCF ratio	-13.27	-16.8	-19.36	-15.16	-16.27
PFCF ratio	-10.95	-14.26	-15.58	-11.54	-10.83
P/B Ratio	10.17	5.57	4.03	5.17	5.32
PTB ratio	10.17	5.57	4.03	5.17	5.32
EV to sales	22.45	67.17	18.24	13.92	6.74
Enterprise value over EBITDA	-10.03	-12.52	-14.92	-11.01	-14.8
EV to operating cash flow	-12.81	-16.17	-16.52	-13.17	-14.32
EV to free cash flow	-10.58	-13.72	-13.3	-10.02	-9.53
Earnings yield	-0.1	-0.07	-0.06	-0.09	-0.05
Free cash flow yield	-0.09	-0.07	-0.06	-0.09	-0.09
Debt to equity	0.28	0.15	0.11	0.2	0.26
Debt to assets	0.17	0.1	0.08	0.14	0.16
Net debt to EBITDA	0.36	0.49	2.56	1.66	2.01
Current ratio	4.1	4.61	4.76	4.63	2.32
Interest coverage	-105.12	-4.9K	91.31	-34.1	-32.32
Income quality	0.79	0.8	0.92	0.75	1.31
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	2.17	4.19	1.24	1.16	0.69
Intangibles to total assets	0.03	0.01	0.01	0.01	0.02
Capex to operating cash flow	0.21	0.18	0.24	0.31	0.5
Capex to revenue	-0.37	-0.74	-0.27	-0.33	-0.24
Capex to depreciation	-8.52	-7.2	-6.78	-7.08	-6.63
Stock based compensation to revenue	0.31	0.59	0.2	0.21	0.15
Graham number	76.17	141.42	151.86	136.31	80.25
ROIC	-0.75	-0.37	-0.2	-0.34	-0.29
Return on tangible assets	-0.61	-0.29	-0.17	-0.32	-0.15
Graham Net	6.96	36.22	50.77	27.25	13.96
Working capital	886.65M	3.89B	6.01B	3.7B	2.39B
Tangible asset value	925.44M	3.82B	6.14B	4.29B	3.46B
Net current asset value	538.76M	3.23B	5.21B	2.72B	1.97B
Invested capital	0.28	0.15	0.11	0.2	0.26
Average receivables	62.79M	76.24M	289.92M	336.67M	284.53M
Average payables	117.89M	177.22M	247.18M	278.59M	304.95M
Average inventory	22.4M	58.92M	165.96M	262.49M	349.23M
Days sales outstanding	62.06	94.15	155.2	44.64	58.77
Days payables outstanding	44.77	62	58.97	55.84	247.96
Days of inventory on hand	10.44	23.87	54.53	53.48	327.44
Receivables turnover	5.88	3.88	2.35	8.18	6.21
Payables turnover	8.15	5.89	6.19	6.54	1.47
Inventory turnover	34.97	15.29	6.69	6.82	1.11
ROE	-0.97	-0.41	-0.23	-0.46	-0.25
Capex per share	-2.64	-2.74	-3.39	-4.55	-5.57

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.66	4.3	5.69	7.46	6.1
Net income per share	-4.29	-3.34	-3.64	2.06	-3.53
Operating cash flow per share	-3.07	-5.41	-2.81	-0.75	-2.13
Free cash flow per share	-4.71	-6.62	-3.97	-2.49	-3.73
Cash per share	43.7	36.79	33.6	30.33	30.61
Book value per share	42.24	39.91	36.3	35.95	33.99
Tangible book value per share	41.33	39.53	35.85	35.44	33.27
Share holders equity per share	42.24	39.91	36.3	35.95	33.99
Interest debt per share	8.76	4.9	6.53	5.71	8.81
Market cap	22.82B	22.45B	18.66B	18.83B	18.77B
Enterprise value	19.84B	19.46B	15.92B	16.34B	16.52B
P/E ratio	-12.81	-16.11	-12.24	21.85	-12.77
Price to sales ratio	60.04	50.14	31.34	24.1	29.59
POCF ratio	-71.72	-39.82	-63.48	-240.91	-84.69
PFCF ratio	-46.75	-32.57	-44.92	-72.29	-48.31
P/B Ratio	5.21	5.4	4.91	5	5.31
PTB ratio	5.21	5.4	4.91	5	5.31
EV to sales	52.21	43.45	26.75	20.91	26.04
Enterprise value over EBITDA	-42.36	-52.41	-53.73	-121.97	-45.89
EV to operating cash flow	-62.36	-34.51	-54.18	-209.08	-74.53
EV to free cash flow	-40.64	-28.23	-38.34	-62.74	-42.51
Earnings yield	-0.02	-0.02	-0.02	0.01	-0.02
Free cash flow yield	-0.02	-0.03	-0.02	-0.01	-0.02
Debt to equity	0.2	0.13	0.18	0.15	0.26
Debt to assets	0.14	0.09	0.12	0.1	0.16
Net debt to EBITDA	6.36	8.06	9.22	18.57	6.26
Current ratio	4.63	3.75	3.13	3.16	2.32
Interest coverage	-25.72	10.82	-59.92	-7.34	-43.26
Income quality	0.71	1.62	0.77	-0.36	0.6
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	3.32	0.91	0.71	0.58	0.75
Intangibles to total assets	0.01	0.01	0.01	0.01	0.02
Capex to operating cash flow	0.53	0.22	0.41	2.33	0.75
Capex to revenue	-0.45	-0.28	-0.2	-0.23	-0.26
Capex to depreciation	-9.44	-6.28	-5.44	-8.47	-7.01
Stock based compensation to revenue	0.21	0.17	0.17	0.12	0.15
Graham number	63.87	54.81	54.55	40.8	51.97
ROIC	-0.09	-0.08	-0.07	-0.03	-0.09
Return on tangible assets	-0.07	-0.06	-0.07	0.04	-0.06
Graham Net	27.08	23.34	19.12	17.55	14
Working capital	3.7B	3.45B	3B	2.77B	2.39B
Tangible asset value	4.29B	4.12B	3.75B	3.71B	3.46B
Net current asset value	2.72B	2.9B	2.47B	2.29B	1.97B
Invested capital	0.2	0.13	0.18	0.15	0.26
Average receivables	187.91M	252.66M	335.15M	346.38M	375.25M
Average payables	273.43M	268.07M	254.17M	304.42M	328.48M
Average inventory	286.63M	289.67M	309.16M	319.13M	366.53M
Days sales outstanding	41	66.76	51.12	40.85	56.16
Days payables outstanding	51.06	265.59	46.32	319.46	220.65
Days of inventory on hand	48.91	326.81	55.75	296.17	291.37
Receivables turnover	2.19	1.35	1.76	2.2	1.6
Payables turnover	1.76	0.34	1.94	0.28	0.41
Inventory turnover	1.84	0.28	1.61	0.3	0.31
ROE	-0.1	-0.08	-0.1	0.06	-0.1
Capex per share	-1.64	-1.21	-1.16	-1.74	-1.6

BGNE Frequently Asked Questions

What is BeiGene, Ltd. stock symbol ?

BeiGene, Ltd. is a US stock , located in Cambridge of Ma and trading under the symbol BGNE

What is BeiGene, Ltd. stock quote today ?

BeiGene, Ltd. stock price is $132.13 today.

Is BeiGene, Ltd. stock public?

Yes, BeiGene, Ltd. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 261.91K
Market Capitalization 15.53B
Employee 10.6K
CEO Mr. John V. Oyler
Headquarters Cambridge,MA,US
IPO Date 2016-02-03
Website https://www.beigene.com

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.